How much? Eyes water as first gene therapy Glybera approaches the market
This article was originally published in Scrip
Glybera (alipogene tiparvovec), the first ever approved gene therapy, could soon reach its first patients, two years after its EU approval, highlighting the rocky road to market that such products must travel. The Italian firm Cheisi has filed a price in Germany where the drug is now available that equates to around €1.1m for a typical patient, making it the world's most expensive drug.